Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor

Current Medical Research and Opinion

Volumn 26, Issue 5, 2010, Pages 1097-1108

  Almeida, Luis ^a,b,c   Loureiro, Ana I ^a   Vaz Da Silva, Manuel ^a   Torrão, Leonel ^a   Maia, Joana ^a   Fernandes Lopes, Carlos ^a   Falcão, Amlcar ^d   Igreja, Bruno ^a   Wright, Lyndon ^a   Soares Da Silva, Patricio ^a,b  

^a Bial Portela and CSA S Mamede Do Coronado ^*  (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d 4Health Ltd   (Portugal)

Author keywords

Catechol O methyltransferase inhibitors; Chronopharmacokinetics; Chronopharmacology; Nebicapone; Parkinsons disease

Indexed keywords

1 (3,4 DIHYDROXY 5 NITROPHENYL) 2 PHENYLETHANONE; ASPARTATE AMINOTRANSFERASE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; NEBICAPONE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRY THROAT; EPIGASTRIC PAIN; FEMALE; HEADACHE; HEARTBURN; HUMAN; LOW BACK PAIN; MALE; METHYLATION; MYALGIA; NAUSEA; ORTHOSTATIC HYPOTENSION; OTALGIA; PARKINSON DISEASE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; SIDE EFFECT; SWEATING; THORAX PAIN; VISUAL IMPAIRMENT; VOMITING;

ACETOPHENONES; ADOLESCENT; ADULT; CATECHOL O-METHYLTRANSFERASE; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; YOUNG ADULT;

EID: 77951076930     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003694472     Document Type: Article

References (16)

1. Almeida L, Soares-da-Silva P. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans. Drugs R D 2003;4:207-217
2. Almeida L, Soares-da-Silva P. Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects. J Clin Pharmacol 2003;43:1350-1360
3. Silveira P, Vaz-da-Silva M, Almeida L, et al. Pharmacokinetic-pharmacody- namic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. Eur J Clin Pharmacol 2003;59:603-609
4. Almeida L, Vaz-da-Silva M, Silveira P, et al. Pharmacokinetic-pharmacody- namic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. Clin Neuropharmacol 2004;27:17-24
5. Vaz-da-Silva M, Loureiro AI, Nunes T, et al. Pharmacokinetic-pharmacody- namic interaction between nebicapone, a novel catechol-O-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg: randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Drugs R D 2008;9:435-446
6. Nunes T, Machado R, Rocha JF, et al. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel COMT inhibitor, and controlled release levodopa/benserazide: a single-centre, phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. Clin Ther 2009;31:2258-2271
7. Almeida L, Falcao A, Vaz-da-Silva M, et al. Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Eur J Clin Pharmacol 2008;64:961-966
8. Ferreira J, Almeida L, Cunha L, et al. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase (COMT) activity and motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 2008;31:2-18
9. Loureiro AI, Bonifacio MJ, Fernandes-Lopes C, et al. Human metabolism of nebicapone (BIA 3-202), a novel catechol-O-methyltransferase inhibitor: characterization of in vitro glucuronidation. Drug Metab Dispos 2006;34:1856-1862
10. Palma PN, Bonifacio MJ, Almeida L, et al. Restoring dopamine levels. In: Smith HJ, Simons C, Sewell RDE, eds. Protein Misfolding in Neurodegenerative Diseases. Boca Raton, FL, USA: CRC Press, 2008:415-445
11. Bruguerolle B. Chronopharmacokinetics current status. Clin Pharmacokinet 1998;35:83-94
12. Ferreira JJ, Almeida L, Cunha L, et al. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol 2008;31:2-18
13. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-428
14. Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49:1066-1071
15. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 1997;49:665-671
16. Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 2000;57:263-267